NeuroPace NPCE
NASDAQ NPCE
$14.50 -0.26 (-1.76%)
As of: Sep 9, 2026 · 3:59 PM EDT

NeuroPace (NPCE) Liabilities from Discontinued Operations (2025)

NeuroPace (NPCE) posted Liabilities from Discontinued Operations of $596000.0 for Q4 2025.

Analysis

NeuroPace (NPCE) Liabilities from Discontinued Operations (2025) Analysis & Trends

NeuroPace has reported Liabilities from Discontinued Operations for 1 years, with the latest figure at $596000.0 in Q4 2025.

  • On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to $596000.0 in Q4 2025; TTM through Dec 2025 was $596000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $596000.0, changed N/A from the prior year.
  • Liabilities from Discontinued Operations was $596000.0 for Q4 2025 at NeuroPace.
  • The five-year high for Liabilities from Discontinued Operations was $596000.0 in Q4 2025, with the low at $596000.0 in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 183.04 Bn 177.44 Bn 7.27 Bn
2 Intuitive Surgical 125.02 Bn 119.81 Bn 1.96 Bn
3 Medtronic 117.84 Bn 109.02 Bn 6.34 Bn
4 Stryker 105.50 Bn 102.02 Bn 4.50 Bn
5 Boston Scientific 66.27 Bn 65.73 Bn 3.85 Bn
6 Edwards Lifesciences 49.60 Bn 45.35 Bn 1.35 Bn
7 Alcon 33.70 Bn 32.24 Bn 1.68 Bn
8 Dexcom 32.06 Bn 30.11 Bn 830.00 Mn
9 Steris 21.02 Bn 20.54 Bn 684.20 Mn
10 NeuroPace 493.15 Mn 441.45 Mn 18.91 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 596,000.00